PMID- 34461272
OWN - NLM
STAT- MEDLINE
DCOM- 20211012
LR  - 20211012
IS  - 1879-0461 (Electronic)
IS  - 1040-8428 (Linking)
VI  - 166
DP  - 2021 Oct
TI  - Efficacy and safety profile of avelumab monotherapy.
PG  - 103464
LID - S1040-8428(21)00251-1 [pii]
LID - 10.1016/j.critrevonc.2021.103464 [doi]
AB  - Avelumab can kill cancer cells through immune checkpoint inhibition and 
      antibody-dependent cell-mediated cytotoxicity (ADCC). Here, we analyzed the 
      clinical efficacy and adverse events (AEs) in 3935 cancer patients from 21 
      trials. Compared with conventional treatment, avelumab monotherapy was associated 
      with more tumor responses and less AEs. The pooled objective response rate was 
      14.18 % (95 % CI, 10.68 %-18.08 %). More PD-L1 positive patients responded to 
      avelumab monotherapy compared to PD-L1 negative patients. The overall incidence 
      was 73.78 % for all-grade treatment-related AE (TRAE), 14.44 % for high-grade 
      TRAE, 6.07 % for serious adverse event, 0.44 % for fatal adverse event, 17.86 % 
      for all-grade immune-related AE (irAE), and 3.22 % for high-grade irAE. In 
      summary, avelumab monotherapy presents an active anti-tumor activity, shows no 
      sign of increased toxicity due to the ADCC. These characteristics provide 
      rational for further application of avelumab in cancer treatment.
CI  - Copyright (c) 2021 Elsevier B.V. All rights reserved.
FAU - Zhao, Bin
AU  - Zhao B
AD  - The Second Affiliated Hospital & Yuying Children's Hospital, Wenzhou Medical 
      University, Wenzhou, 325027, China. Electronic address: doctorbinzhao@126.com.
FAU - Gao, Meiling
AU  - Gao M
AD  - The Second Affiliated Hospital & Yuying Children's Hospital, Wenzhou Medical 
      University, Wenzhou, 325027, China.
FAU - Zhao, Hong
AU  - Zhao H
AD  - The Cancer Center of the Fifth Affiliated Hospital, Sun Yat-Sen University, 
      Zhuhai, 519001, China.
FAU - Zhao, Jiaxin
AU  - Zhao J
AD  - Zhuhai People's Hospital, Zhuhai Hospital Affiliated with Jinan University, 
      Zhuhai, 519001, China.
FAU - Shen, Xian
AU  - Shen X
AD  - The Second Affiliated Hospital & Yuying Children's Hospital, Wenzhou Medical 
      University, Wenzhou, 325027, China. Electronic address: doctorxianshen@163.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210828
PL  - Netherlands
TA  - Crit Rev Oncol Hematol
JT  - Critical reviews in oncology/hematology
JID - 8916049
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (B7-H1 Antigen)
RN  - KXG2PJ551I (avelumab)
SB  - IM
MH  - *Antibodies, Monoclonal/adverse effects
MH  - Antibodies, Monoclonal, Humanized/adverse effects
MH  - Antibody-Dependent Cell Cytotoxicity
MH  - *B7-H1 Antigen
MH  - Humans
OTO - NOTNLM
OT  - Avelumab
OT  - Checkpoint inhibitors
OT  - Efficacy
OT  - Immunotherapy
OT  - Safety
OT  - Toxicity profile
EDAT- 2021/08/31 06:00
MHDA- 2021/10/13 06:00
CRDT- 2021/08/30 20:14
PHST- 2019/04/30 00:00 [received]
PHST- 2021/03/11 00:00 [revised]
PHST- 2021/08/19 00:00 [accepted]
PHST- 2021/08/31 06:00 [pubmed]
PHST- 2021/10/13 06:00 [medline]
PHST- 2021/08/30 20:14 [entrez]
AID - S1040-8428(21)00251-1 [pii]
AID - 10.1016/j.critrevonc.2021.103464 [doi]
PST - ppublish
SO  - Crit Rev Oncol Hematol. 2021 Oct;166:103464. doi: 
      10.1016/j.critrevonc.2021.103464. Epub 2021 Aug 28.